ActivePhase 4ACTRN12611000065998

The effect of zolendronic acid on the clinical resolution of acute midfoot Charcot foot


Sponsor

Pirkanmaa Hospital District

Enrollment

40 participants

Start Date

Apr 1, 2002

Study Type

Interventional

Conditions

Summary

Diabetic Charcot foot is a rare but devastating foot complication of diabetes mellitus. The resolution of the acute form of Charcot foot needs immobilisation in a cast and total non-weight bearing for at least 12 to 16 weeks. Increased osteoclastic activity is thought to be one of the main pathological feature of the acute Charcot foot. That is why bisphosphonates are widely used in the treatment of acute Charcot process. There are some preliminary studies about the effect of bisphosphonates on the resolution of acute Charcot foot. In this study we investigated the effect of zoledronic acid on the clinical resolution of acute Charcot foot.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria1

  • Patients with acute unilateral Charcot foot and type I or type II diabetes mellitus

Exclusion Criteria1

  • Serum creatine >400 umol/l

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Patients with acute Charcot foot receive either 3 intravenous infusions of placebo (normal saline) or 4mg of zolendronic acid (bisphosphonate) in 4 week intervals

Patients with acute Charcot foot receive either 3 intravenous infusions of placebo (normal saline) or 4mg of zolendronic acid (bisphosphonate) in 4 week intervals


Locations(1)

Finland

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000065998